Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response.
Saved in:
| Title: | Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response. |
|---|---|
| Authors: | Skuli SJ; Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Bakayoko A; Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Kruidenier M; Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Manning B; Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Immunology, Microenvironment & Metastasis Program, Ellen and Ronald Caplan Cancer Center, Wistar Institute, Philadelphia, PA, USA., Pammer P; Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Salimov A; Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Riley O; Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Brake-Sillá G; Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Dopkin D; Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Bowman M; Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA, USA., Martinez-Gutierrez LN; Department of Medicine - Leukemia, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Anderson CC; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Reisz JA; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Buono R; Department of Molecular Biology and Biochemistry, University of California, Irvine, CA, USA., Paul M; Department of Molecular Biology and Biochemistry, University of California, Irvine, CA, USA., Saland E; Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Toulouse, France., Liccardo F; Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Toulouse, France., DeVine A; Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Wong S; Department of Research and Development, Tevogen Bio, Philadelphia, PA, USA., Xu JP; Department of Pharmacology, The University of Pennsylvania, Philadelphia, PA, USA., Nee E; Department of Pharmacology, The University of Pennsylvania, Philadelphia, PA, USA., Hausler R; Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Boettcher S; Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland., Sebti SM; Department of Pharmacology and Toxicology and Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, USA., Lai C; Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Maxwell KN; Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Abramson Family Cancer Research Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Corporal Michael Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA., Sarry JE; Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Toulouse, France.; LabEx Toucan, Toulouse, France.; Équipe Labellisée Ligue Nationale Contre le Cancer, Toulouse, France., Fruman DA; Department of Molecular Biology and Biochemistry, University of California, Irvine, CA, USA., D'Alessandro A; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Mesaros C; Department of Pharmacology, The University of Pennsylvania, Philadelphia, PA, USA., Keith B; Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA, USA.; Abramson Family Cancer Research Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Simon MC; Abramson Family Cancer Research Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, PA, USA., Sung PJ; Department of Medicine - Leukemia, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Wertheim G; Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA., Skuli N; Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA., Bowman RL; Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA, USA., Matthews A; Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Carroll M; Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. carroll2@pennmedicine.upenn.edu.; Corporal Michael Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA. carroll2@pennmedicine.upenn.edu. |
| Source: | Leukemia [Leukemia] 2025 Sep; Vol. 39 (9), pp. 2087-2098. Date of Electronic Publication: 2025 Jul 09. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
